Revisiting potential druggable targets against SARS-CoV-2 and repurposing therapeutics under preclinical study and clinical trials: a comprehensive review

Abdullah Al Mamun Sohag*, Md Abdul Hannan, Sadaqur Rahman, Motaher Hossain, Mahmudul Hasan, Md Kawsar Khan, Amena Khatun, Raju Dash, Md Jamal Uddin

*Corresponding author for this work

    Research output: Contribution to journalReview articlepeer-review

    14 Citations (Scopus)

    Abstract

    Coronavirus disease-19 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is one of the most contagious diseases in human history that has already affected millions of lives worldwide. To date, no vaccines or effective therapeutics have been discovered yet that may successfully treat COVID-19 patients or contain the transmission of the virus. Scientific communities across the globe responded rapidly and have been working relentlessly to develop drugs and vaccines, which may require considerable time. In this uncertainty, repurposing the existing antiviral drugs could be the best strategy to speed up the discovery of effective therapeutics against SARS-CoV-2. Moreover, drug repurposing may leave some vital information on druggable targets that could be capitalized in target-based drug discovery. Information on possible drug targets and the progress on therapeutic and vaccine development also needs to be updated. In this review, we revisited the druggable targets that may hold promise in the development of the anti-SARS-CoV-2 agent. Progresses on the development of potential therapeutics and vaccines that are under the preclinical studies and clinical trials have been highlighted. We anticipate that this review will provide valuable information that would help to accelerate the development of therapeutics and vaccines against SARS-CoV-2 infection.

    Original languageEnglish
    Pages (from-to)919-941
    Number of pages23
    JournalDrug Development Research
    Volume81
    Issue number8
    Early online date6 Jul 2020
    DOIs
    Publication statusPublished - Dec 2020

    Keywords

    • clinical trial
    • COVID-19
    • drug repurposing
    • drug targets
    • therapeutics
    • vaccines

    Fingerprint

    Dive into the research topics of 'Revisiting potential druggable targets against SARS-CoV-2 and repurposing therapeutics under preclinical study and clinical trials: a comprehensive review'. Together they form a unique fingerprint.

    Cite this